Double immunotherapy combo aims to boost lung cancer surgery outcomes
NCT ID NCT05825625
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial investigates whether adding two immunotherapy drugs—tiragolumab and atezolizumab—to standard chemotherapy before and after surgery can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls 35 adults with stage II to IIIB disease. The main goal is to see how many patients have a major pathological response (fewer than 10% viable tumor cells remaining) after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tiragolumab and atezolizumab (immunotherapy drugs) plus chemotherapy
What this could lead to
If successful, this combination could become a new standard treatment before and after lung cancer surgery, potentially improving cure rates.
What could go wrong
This is a small, early-phase study with only 35 participants, so results may not apply to all patients. Immunotherapy combinations can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thoraxklinik Heidelberg
Heidelberg, 69126, Germany
-
Universitätsklinikum Essen (AöR)-Westdeutsches Tumorzentrum Essen
Essen, 45147, Germany